Evidence map›Paper›PMID 41266436›Full record

ArticleNPJ Parkinson's disease2025

Discriminating between proposed Brain-First and Body-First Parkinson's disease using conventional and radiomics-enhanced dopamine transporter SPECT image analysis.

Giovanni Palermo, Gayanè Aghakhanyan, Gabriele Bellini, Sara Giannoni, Gabriele Vadi, Roberto Francischello, Giovanna Nonne, Maria Giulia Tedeschi, Riccardo Morganti, Daniela Frosini and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Giovanni Palermo *Center for Neurodegenerative Diseases-Parkinson's Disease and Movement Disorders, Unit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Gayanè Aghakhanyan *Regional Center of Nuclear Medicine, Department of Translational Research and of New Surgical and Medical Technology, University of Pisa, Pisa, Italy.
Gabriele BelliniCenter for Neurodegenerative Diseases-Parkinson's Disease and Movement Disorders, Unit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Sara GiannoniNeurology Department, San Giuseppe Hospital, Empoli, Italy.
Gabriele VadiCenter for Neurodegenerative Diseases-Parkinson's Disease and Movement Disorders, Unit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Roberto FrancischelloDepartment of Translational Research and of New Surgical and Medical Technology, Academic Radiology, University of Pisa, Pisa, Italy.
Giovanna NonneRegional Center of Nuclear Medicine, Department of Translational Research and of New Surgical and Medical Technology, University of Pisa, Pisa, Italy.
Maria Giulia TedeschiCenter for Neurodegenerative Diseases-Parkinson's Disease and Movement Disorders, Unit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Riccardo MorgantiSection of Statistics, University of Pisa, Pisa, Italy.
Daniela FrosiniCenter for Neurodegenerative Diseases-Parkinson's Disease and Movement Disorders, Unit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Nicola PaveseClinical Ageing Research Unit, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Duccio VolterraniRegional Center of Nuclear Medicine, Department of Translational Research and of New Surgical and Medical Technology, University of Pisa, Pisa, Italy.
Roberto CeravoloCenter for Neurodegenerative Diseases-Parkinson's Disease and Movement Disorders, Unit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. roberto.ceravolo@unipi.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two Parkinson's disease subtypes-"Brain-First" and "Body-First"-have been proposed based on putative sites of onset. We examined whether "Body-First" markers relate to more symmetric striatal [

Identifiers

PMID41266436
PMCPMC12635385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.